La gestione della terapia ipoglicemizzante nel paziente con nefropatia da diabete mellito tipo 2

2019 ◽  
Vol 31 (3) ◽  
pp. 155-159
Author(s):  
Francesco Manetti
Keyword(s):  
Risk Factors ◽  
Impaired Renal Function ◽  
Renal Damage ◽  
Drug Dosage ◽  
Risk Profile ◽  
Hypoglycemic Agents ◽  
Cardiovascular Risk Profile ◽  
Oral Hypoglycemic Agents ◽  
Diabete Mellito ◽  
Associated Risk Factors

Chronic kidney disease (CKD) is constantly increasing in terms of prevalence and incidence. Subjects with impaired renal function, even if only in the presence of micro/macroalbuminuria, have an increased cardiovascular risk profile. Therefore, we must pay particular attention to the treatment of all associated risk factors. Therapy with oral hypoglycemic agents often requires modulation of drug dosage based on kidney function. Today, there are molecules available that are able not only to induce cardiovascular protection, but also to slow the progression of renal damage.

scholarly journals La gestione della terapia ipoglicemizzante nel paziente con nefropatia da diabete mellito tipo 2

2019 ◽  
Vol 31 (3) ◽  
pp. 155-159
Author(s):  
Francesco Manetti
Keyword(s):  
Renal Damage ◽  
Drug Dosage ◽  
Risk Profile ◽  
Hypoglycemic Agents ◽  
Cardiovascular Risk Profile ◽  
Oral Hypoglycemic Agents ◽  
Diabete Mellito ◽  
Associated Risk Factors ◽  
Hypoglycemic Therapy

Management of hypoglycemic therapy in patients with type 2 diabetes mellitus and nephropathy Chronic kidney disease (CKD) is constantly increasing in terms of prevalence and incidence. Subjects with impaired renal function, even if only in the presence of micro/macroalbuminuria, have an increased cardiovascular risk profile. Therefore, we must pay particular attention to the treatment of all associated risk factors. Therapy with oral hypoglycemic agents often requires modulation of drug dosage based on kidney function. Today, there are molecules available that are able not only to induce cardiovascular protection, but also to slow the progression of renal damage.

Results of a Survey of Cardiovascular Risk Factor Prevalence Amongst Health Care Workers

2000 ◽  
Vol 45 (3) ◽  
pp. 84-85 ◽  
Author(s):  
S.R. McEwan ◽  
N.G. Dewhurst ◽  
F. Daly ◽  
C.D. Forbes ◽  
J.J.F. Belch
Keyword(s):  
Risk Factors ◽  
Health Care ◽  
Cardiovascular Risk ◽  
Health Care Workers ◽  
Risk Profile ◽  
Royal Infirmary ◽  
Cardiovascular Risk Profile ◽  
Risk Factor Prevalence ◽  
Care Workers ◽  
High Prevalence

Summary analyses of screening data were used to ascertain the cardiovascular risk profile in a sample of health care workers in Scotland. A sample of NHS staff (298 women and 78 men) were screened during visits to Perth Royal Infirmary (PRI) in 1996 and 1997. Comparisons were made within subsets and with previous screening studies. Health care workers have been a neglected component of the workforce for receiving education about risk factors. The high prevalence of smokers found in this sample should be a cause for concern.

White Coat Hypertension, Metabolic Risk Factors and Cardiovascular Risk Profile

2014 ◽  
pp. 97-111
Author(s):  
Michele Bombelli ◽  
Rita Facchetti ◽  
Gianmaria Brambilla ◽  
Guido Grassi ◽  
Giuseppe Mancia
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Risk Profile ◽  
Metabolic Risk Factors ◽  
White Coat ◽  
White Coat Hypertension ◽  
Metabolic Risk ◽  
Cardiovascular Risk Profile

Treatment Choices and Patterns in Migraine Patients With and Without a Cardiovascular Risk Profile

Cephalalgia ◽  
2009 ◽  
Vol 29 (3) ◽  
pp. 322-330 ◽  
Author(s):  
EA Wames-van der Heijden ◽  
CC Tijssen ◽  
ACG Egberts
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Observational Study ◽  
Cardiovascular Risk Factors ◽  
Risk Profile ◽  
Treatment Patterns ◽  
Retrospective Observational Study ◽  
Cardiovascular Risk Profile ◽  
Treatment Choices ◽  
Antimigraine Drugs

Treatment patterns in migraine patients with cardiovascular risk factors are largely unknown. A retrospective observational study was conducted to characterize the baseline cardiovascular risk profile of new users of specific abortive migraine drugs, and to investigate treatment choices and patterns in patients with and without a known cardiovascular risk profile. New users of a triptan, ergotamine or Migrafin® ( n = 36 839) from 1 January 1990 to 31 December 2006 were included. Approximately 90 of all new users did not have a clinically recognized cardiovascular risk profile. The percentage of new users with a cardiovascular risk profile did not differ between new users of a triptan, ergotamine or Migrafin® and also did not change during the study period of 17 years. Differences in treatment choices and patterns between migraine patients with and without a known cardiovascular risk profile reveal a certain reticence in prescribing vasoconstrictive antimigraine drugs to patients at cardiovascular risk.

scholarly journals Cardiovascular Risk Profile in Dupuytren’s Disease: A Systematic Review and Meta-Analysis.

2020 ◽  
Author(s):  
Sylvain Mathieu ◽  
Bruno Pereira ◽  
Frederic Dutheil ◽  
Martin Soubrier
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Meta Analysis ◽  
Risk Profile ◽  
Dupuytren’S Disease ◽  
Cardiovascular Risk Profile ◽  
Dupuytren's Disease ◽  
Risk Of Death ◽  
Inverse Variance ◽  
Mean Differences

Abstract Background. Patients with Dupuytren’s disease (DD) may have a higher cardiovascular (CV) risk because of association with diseases with a higher recognized CV risk, such as diabetes. However, DD is not always linked to these diseases; therefore, it seems relevant to assess the CV profile in DD.Methods. We performed a systematic literature review up to April 2020. Differences between DD patients and controls were expressed as standardized mean differences using the inverse-variance method or as odds ratios (ORs) using the Mantel-Haenszel method. Results. We obtained 51 references corresponding to 112,900 DD patients and 2,383,177 controls. We found a higher risk of death (OR=1.72 [95%CI:1.37-2.16]) and CV death (118/974 DD patients vs. 372/3948 controls; OR=1.33 [95%CI:1.07-1.66]) among DD patients compared to controls. DD patients were more often diabetic (OR=3.44 [95% CI:2.69-4.38]). In 17 studies of the general population, the incidence of diabetes was 17.5% among DD patients (11.7-24.2%). DD patients were older, and more often men or alcohol drinkers. The percentage of smokers and levels of blood pressure or total cholesterol were not different among DD patients and controls. No difference was found in triglycerides, but the risk of obesity was significantly lower in DD patients.Conclusions. We found a higher CV risk in DD but not a higher prevalence of CV risk factors, except diabetes. This may be due to the predominance of men or greater number of alcohol drinkers or diabetics. Management of CV risk is important in patients with DD, including research on alcohol consumption or diabetes.

Abstract 15488: Epidemiological Profile of Cardiovascular Risk Factors and Outcomes in Patients With Solid Organ and Haematological Malignancies

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
David Chandrakumar ◽  
Gary Gan ◽  
Urmi Jethwani ◽  
Cindy Li ◽  
Aaia Aladdin ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Composite Endpoint ◽  
Risk Profile ◽  
Solid Organ ◽  
Cardiovascular Risk Profile ◽  
Cardiac Events ◽  
Significant Difference

Introduction: Chemotherapy remains the cornerstone in the management of solid organ malignancies (SOM) and hematological malignancies (HM). Although life-prolonging, it is not without cost, with heart failure and arrhythmia becoming increasingly recognised complications of treatment. Although there is significant overlap in the chemotherapeutic management of SOM and HM, epidemiological information on the differential prevalence of baseline cardiovascular risk factors and outcomes in these populations is scarce. Hypothesis: A differential cardiovascular risk profile and clinical course will be appreciated in patients with SOM and HM undergoing chemotherapy. Methods: Retrospective observational study design. Patients admitted to our institution undergoing chemotherapy for SOM (2014-2018) or HM (2012-2015) were reviewed. Baseline demographic and clinical data was collated and patients were followed for up to five years following chemotherapy for occurrence of major adverse cardiac events (MACE) defined as the development of new-onset heart failure or arrhythmia. Results: 545 hematology and 435 oncology patients with malignancy were assessed. Compared to those with HM, those treated for SOM had a poorer cardiovascular risk profile (table 1). At mean follow-up period of 22.8±17.8 months, no significant difference in the incidence of the composite endpoint (9.4% vs 9.0%, p=0.45) or its components was observed. Higher rates of anthracycline therapy was observed in patients with HM (100% vs 17%, p < 0.01), however its use did not have a differential effect on MACE (12% vs 9%, p=0.25). Conclusions: Compared to patients treated for HM, patients with SOM had a greater burden of cardiovascular risk factors and lower use of anthracycline chemotherapy. Despite this, MACE occurred at similar rates in both groups. The use of anthracyclines was not associated with the development of MACE, suggesting alternative pathways contributing to its development.

Sign in / Sign up

Export Citation Format

Share Document